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Vaccination is arguably one of the greatest accomplishments to the improvement of public 
health and longevity in this lifetime.  It is estimated that vaccinations prevent 2.5 million deaths 
per year and have significantly contributed to a greater than 30-year increase in lifespan from the 
1900s through today. Vaccination has notably decreased both morbidity and mortality. Thus, it has 
improved the quality of life and reduced the economic burden for the population.  Although riddled 
with its controversies and barriers, it remains a mainstay to preventative health.  Children are 
routinely vaccinated, but it was not until 2005 that adult vaccination began to grow in popularity.  
Being an unfamiliar notion to most adults, this crusade met opposition (education/misinformation 
barriers, financial barriers and access). As a result, several interventions have been proposed to 
increase vaccination efforts for the adult population. This paper strives to briefly review 
vaccination and its relevance in the adult population and to discuss the outcome of a process 
improvement goal by Premier Medical Associates to increase vaccination rates for pneumococcus 
and influenza in its adult population.  Premier successfully increased its pneumococcal vaccination 
rates from a baseline of 66% to 78% and influenza’s vaccination rate from 40% to 80% in a one-
year period.  Despite its tremendous successes there were still significant barriers that hindered 
even larger improvements. This paper discusses Premier’s process, successes; also discusses the 
barriers and suggestions to overcome them.   
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1.0 Public Health Relevance 
Population health is an approach aimed at targeting an entire population in order to affect 
the overall health of the general group as opposed to an individual.  It is a common approach in 
Public Health policies such as Tobacco 21, The Clean Air Act or Lead prevention. Following that 
theme, this vaccine initiative carries similar intentions to affect the overall health of a population.  
However, it serves to apply a series of changes to how individual patients engage with healthcare 
with a goal to impact a large subset of the community (Premier Medical Associates’ adult patient 
population) to improve the overall health of that population.  Physicians are in a unique position 
and often have personal relationships with patients.  They have an extreme degree of influence on 
how information is presented.  This project intersects individualized traditional health care via the 
doctor-patient relationship with attempting to move an entire group of patients towards overall 
health.  While a great deal of public health successes hinge upon policy implementation, this newer 
approach is one that is starting to gain strong interest in medical arenas.  Insurance companies see 
value in their members being healthier; thus, utilizing less health care and driving down costs. 
They are therefore rewarding providers with revenue savings when they yield healthier 
populations.  Looking at the bigger picture, cost savings and a healthier population would 
intuitively lead to lower healthcare costs and hopefully impact the percentage of the gross domestic 
product spent on healthcare. 
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2.0 Introduction 
Similar to clean water and the development of penicillin, vaccination is one of the most 
important public health advancements of the eighteenth century. Vaccinations have saved 
numerous lives and have sustained the quality of lives of many by reducing the morbidity 
associated with surviving many of these preventable diseases. Vaccination provides active 
immunity.  It creates immunity by allowing the body to develop protection against an infection by 
exposure to a portion of a particle that causes the infection; thus allowing the human body the 
ability to make antibodies to protect itself from a true encounter with the actual organism. (Riedel, 
2005) It does this with relatively low risk. Serious reactions are rare. Adults who receive influenza 
vaccine, for example, can experience minor reactions such as localized site pain (28%), headache 
(16%) and malaise (10%). (Centers for Disease Control and Prevention, n.d.)  Despite the health 
benefits of vaccination, there are many reasons that individuals choose not to be vaccinated. 
Among the reasons are access, cost, incomplete information, and personal choice; leaving them 
vulnerable to many preventable infections. Currently twenty-six vaccines are licensed for use. The 
vaccines relevant to this paper are Pneumococcal and Influenza. Both vaccines prevent illnesses 
that can result in significant morbidity and mortality, ravaging the lives of many. In the US, 
pneumococcus is responsible for 7 million cases of otitis media, 500,000 cases of pneumonia, 
50,000 cases of sepsis, 3,000 cases of meningitis and 40,000 deaths. (Merck Manual, 2019) 
Influenza is no less imposing. It is estimated that it poses an economic burden of over $87 billion 
dollars a year and can result in significant morbidity and/or mortality. Lost earnings of $16.3 
billion dollars occur annually as a result of the influenza virus (Puturi, Muscatello, Stockwell, & 
Newall, 2018) 
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3.0 Background  
3.1 What Is Vaccination? 
The notion that one might develop active immunity against an illness after contracting it 
was noted in 430 BC by the Thucydides. Similarly, populations in China attempted to cause 
artificial active immunity via dangerous rituals of exposure to dried smallpox pustules to develop 
protections from this deadly illness. (Rappuoli, Pizza, & DeGregorio, 2014) Later, a revolutionary 
idea was first introduced by Edward Jenner in 1796 after an observation that milkmaids who had 
previously contracted cowpox were later immune to developing smallpox. The revelation that an 
illness could later protect against another encounter with that illness was the beginning of 
understanding how to manipulate the immune system in such a way that has ultimately led to 
extending the lifespan of generations, growing the world’s population, and protecting vulnerable 
individuals who might otherwise succumb to these infections.  Vaccination is essentially providing 
the body’s immune system with a memory of what a certain bacteria or virus may “look like” in 
order to be prepared to fight off infection.  It is the equivalent of having a “wanted poster” in the 
body to warn and prepare for illness.  The human immune system protects the body through a 
complicated interaction of cells communicating with one another. To simplify the process, white 
blood cells protect the body from invading infection.  White blood cells come in three varieties: 
Macrophages, T –Lymphocytes, and B- Lymphocytes.  While macrophages generally travel in the 
blood, they can exit and reenter to engulf and kill foreign material as well as damaged or aging 
cells in the body.  The B and T cells do the majority of the surveillance for the body. B- 
Lymphocytes clean up antigens left over from the macrophages and produce antibodies to protect 
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against a future infection. T- Lymphocytes attack and kill the body’s cells that have become 
infected. A subset of T cells act as memory cells to help the body recall if a particular organism is 
encountered in the future.  Vaccination is an artificially simulated version of what the body does 
in the event of an infection.  The process of vaccination mimics an infection via the introduction 
of a protein or particle from the potentially infecting organism in order to make the body’s T and 
B Lymphocyte cells generate protection for the body in the event that this organism attempts to 
enter the body. (Center's for Disease Control and Prevention, 2013)  This process allows for an 
individual to benefit from the protection without naturally encountering the actual illness and 
avoiding the potential morbidity or mortality associated with an infection.  It also allows for herd 
immunity that occurs when a large number of individuals are vaccinated resulting in protection of 
unprotected individuals in a community. In the case of Pneumococcal vaccine, a part of the outer 
sugar-coated capsule is used to induce antigenicity. Influenza, having several vaccines market and 
occurring in both live- attenuated and killed versions, generally focuses on the hemagglutinin 
protein to generate antibodies to attack an influenza virus entering the body. (Gomez Lorenzo & 
Fenton, 2013) 
3.2 Pneumococcal Infection 
Pneumococcus is a gram-positive spherical (coccus) bacteria spread most commonly by 
respiratory droplets that are expelled when an infected individual coughs or sneezes.  The bacteria 
commonly cause fever, general malaise, ear, sinus, lung (pneumonia), blood and spinal fluid 
infections.  This bacterium is very prevalent in the younger age groups but affects the older 
population especially if they have certain risk factors. Generally, any illnesses that compromise 
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the immune system lend an increased risk of susceptibility to Pneumococcus.  These conditions 
are heart disease, COPD, diabetes mellitus, chronic kidney problems, chronic liver disease, chronic 
alcohol use, or any chronic illnesses that generally impact the strength of the immune system. 
(Merck Manual, 2019)  Pneumococcal pneumonias are one of the most common causes of death 
worldwide.  In the United States alone it is responsible for 60,000 deaths annually. (Merck Manual, 
2019) It is a common co-infector along with influenza and as a result, it is the eighth most common 
cause of death. Similarly, it ranks as the leading cause of death due to infection in hospitalized 
individuals.  Its significance is staggering.  While antibiotics can treat this infection if diagnosed 
in a timely manner, it has become increasingly difficult to treat Pneumococcus due to increasing 
antibiotic resistance to commonly used antibiotics.  A delay in the initiation of treatment of an 
individual who may not assume their symptoms warrant attention may make it impossible to beat 
this illness. Prevention of this infection can be attempted through vaccination.  Although there are 
90 strains of infectious pneumococcus, 7 strains accounted for the majority of the illnesses in 2000. 
(Center's for Disease Control and Prevention, 2019)  There are two pneumococcal vaccines 
available; a conjugate PCV13 and a polysaccharide vaccine (PPSV23).  Thirteen strains are 
covered in the PCV 13 vaccine that was released in 2010. PSSV23 was licensed in 1977. Twenty-
three strains are represented in the polysaccharide vaccine. There is an overlap of 7 strains found 
in the vaccines. There are obstacles in regard to prevention of Pneumococcal infections and its 
associated morbidity. Areas of focus are decreasing the overuse of antibiotics, developing vaccines 
to cover the unprotected strains, enhanced detection methods through laboratory testing, and 
increasing the vaccination rates for the currently underutilized PCV-13 and PPSV23 vaccines.  
Providing a clear message regarding vaccination safety, cost, and insurance related coverage 
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concerns are hurdles that can be influenced to affect the vaccination rate. (Shen, Warnock, Selna, 
Chu, & Kelman, 2019) 
The recommendations for adult Pneumococcal vaccination are even a bit confusing for 
most clinicians which may in turn contribute to the decreased utilization of it by the medical 
community. If individuals 19-64 meet criteria for chronic medical conditions or they smoke 
cigarettes, then one dose of PPSV23 is recommended. Chronic medical conditions include 
conditions such as heart disease, lung disease, diabetes mellitus, cerebrospinal fluid leaks, cochlear 
implants, alcoholism, and liver disease. Ages 19 and older with immunocompromising conditions 
to include sickle cell disease / hemoglobinopathy, congenital or acquired asplenia, congenital or 
acquired immunodeficiency, HIV infection, chronic renal failure, nephrotic syndrome, leukemia, 
lymphoma, Hodgkin’s disease, generalized malignancy, solid organ transplantation, solid organ 
transplant,  cochlear implant, CSF leak, or general immunosuppression receive one dose of PCV-
13 followed in eight weeks by one dose of PPSV23, but  at least five years after any previous  
PPSV23 administration and again at  65-years of age.  Ages 65 years old and older receive one 
dose of PCV-13 followed by PPSV-23 one year after PCV-13, but at least five years after the last 










Table 1 Adult Immunization Recommendations for Pneumococcal and Influenza 
 
 
A common clinical error is administering PPSV23 every five years. Since the Adult 
Immunization Collaborative has ended, the ACIP has reevaluated its recommendation and as of 
June 2019, PCV-13 is no longer routinely recommended.  This change was due to a re-review of 
the current literature with a determination that the overall disease burden is steadily decreasing 
due to mandatory vaccination of children since 2000. This along with a risk-benefit analysis lead 
to this change. (Matanock A, 2019) 
3.3 Influenza Infection 
Influenza is caused by a viral pathogen known to primarily infect the respiratory tract 
causing a constellation of symptoms:  fever, coryza, malaise myalgias, headache.  The virus is 
characterized by its nucleoproteins as type A, B, C and D.  C does not cause typical influenza 
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illness and therefore is not often discussed.  D does not usually affect humans.  When looking at 
influenza A and B, there are two major components to the structure of the influenza virus.   
Hemagglutinin (H) is the surface glycoprotein that allows the virus to bind to host cells and the 
neuraminidase (NA) which enzymatically dissolves the membrane of the host cells thereby 
allowing viral release.   There are 18 H and 11 NA unique options yielding 198 combinations but 
only a few affect humans (Merch Manual Professional Version, 2019). While influenza is present 
throughout the year, it tends to cause seasonal illness leading to epidemics.   It is known to cause 
pandemics periodically and its infectivity is thought to have a pattern.  It is spread through 
respiratory droplets that become airborne with coughing and sneezing.  It effects all age groups 
but has a propensity to cause more complicated illness in children less than four years of age, 
adults greater than 65-years old, pregnant women, individuals on chronic aspirin therapy, 
individuals with chronic illnesses especially chronic respiratory illness with impaired clearance of 
respiratory secretions.  Complications of influenza infection are most often pneumonia but can 
also include encephalitis and Reye syndrome.  Influenza is often a co-infector allowing improved 
susceptibility of agents like pneumococcus and often leading to respiratory failure and possibly 
death. The Centers for Disease Control and Prevention (CDC) estimated that greater than 700,000 
hospitalizations and approximately 50,000 deaths result from seasonal influenza annually with 
more than 80% of these complications occurring in the 65-year and older age groups (Influenza, 
2019 October).   Although there have been various antiviral medications developed to help combat 
the illness, drug resistance has already ensued, and vaccination remains the mainstay of prevention 
in such an insidious illness.  Currently in the US, the ACIP recommends annual, universal 
vaccination with increased emphasis on high risk groups. The vaccine comes as both trivalent (2 
A strains, 1 B strain) and quadrivalent (2A strains and 2 B strains). The type of vaccine comes in 
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two varieties; a killed inactivated vaccine (IIV) and a live-attenuated vaccine (LAIV).  The live 
vaccine is given intranasally to ages 2-49 with the exception of high- risk individuals, pregnant 
women, those on long term aspirin therapy and household contacts of immunocompromised 
individuals. The IIV vaccine is recommended for 6 months of age and older.  Both vaccines are 
contraindicated for those who have had a condition known as Guillain-Barre syndrome.   Egg 
allergy is no longer a contraindication as there are newer recombinant vaccines not grown in eggs 
and it is thought to be more a theoretical risk for most people with egg protein allergies. (Kelso, 
2018) 
Vaccination is more commonplace in the pediatric community where prevention of 
common childhood diseases has become a routine public health intervention to prevent the spread 
of disease and reduce mortality.  This was found to be a necessity as our communities began to 
grow and become vastly interactive.   As of recent there has been increasing pushback from citizens 
in the community wanting transparency and questioning the requirement of vaccination; citing the 
right to personal refusal.  Despite this newer trend vaccines continue to be encouraged, 
recommended and in most instances required to participate in school and other organized 
programs.   This volume of vaccine recipients is not replicated in the adult population. While most 
adults may have received immunizations as children the propensity to continue to receive 
vaccinations drops off sharply in adults. While about 91% of US children receive appropriate 
vaccines and/or exemptions (Centers for Disease Control and Prevention, 2019). The National 
Health interview survey in 2016 states that only 70.4% and 66.9% of adults were vaccinated for 
influenza and pneumococcus respectively. (Centers for Disease Control and Prevention, 
2019)Adults have been accustomed to receiving tetanus immunization for wounds and many may 
have decided to get vaccinated against influenza, but in 2005 there became a major push to improve 
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the immunity in adults who due to chronic illness suffer a great deal of morbidity and economic 
burden from preventable illness.   The Healthy People 2020 Goals currently recommend an adult 
vaccination schedule that includes both universal vaccinations and vaccinations based on risk 
profiles.  (Table1) 
3.4 Vaccine Effectiveness/Side Effects 
Vaccine effectiveness is a longstanding, familiar, and common concern. It is challenging 
to place an accurate numerical value on to what degree a vaccine is effective for each person. There 
are many cofounding factors that complicate the true outcome.  Each individual’s immune system 
is unique. Exposures to illnesses and existing risk factors make it virtually impossible to adequately 
assess this even when controlling for factors that are controllable. Immunogenicity varies per each 
vaccine. It is generally thought that vaccination with Pneumococcal vaccines protect 60-70 percent 
against invasive disease. Strains included in the vaccine are capsular polysaccharide: 
1,3,4,5,6A,6B,7F,9V,14 19A,19F,18C and 23F. These strains are coupled with a noninfective form 
of diphtheria that serves as a conjugate which acts to make the body’s immune systems more 
reactive to the foreign material. (Centers for Disease Control and Prevention, 2019) 
While it is widely known that influenza vaccine effectiveness varies from year to year, 
effectiveness remains in the 40%- 60% range. The vaccine has a better track record of reducing 
the risk of hospitalization from the illness and can even affect the risk of cardiac problems after 
having had influenza. Effectiveness also depends on which strains are circulating amongst the 
population at the time with A(H1N1) and B having better protection in most populations than 
A(H3N2) strains.  Other factors affecting the effectiveness of the influenza vaccine include the 
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health characteristics of the person being vaccinated. In other words, the individual’s ability to 
make adequate antibodies to protect the body will vary. Additionally, congruency of circulating 
strains with the current year’s vaccine play a huge role. If the vaccine given doesn’t match the 
circulating strains it will provide less protection that year. (Rondy, et al., 2017) (Centers for 
Disease Control and Prevention, 2019) Lastly, the number of people in the population being 
vaccinated affect the population in general since less circulating disease provides a decreased 
susceptibility overall for individuals simply by decreased exposure. 
3.5 Is Vaccination as Protective as Natural Infection 
The CAPiTA trial, a randomized placebo-controlled trial studied the effectiveness of PCV-
13, the conjugate vaccine, in a large sample of adults (85,000) over the age of 65 years of age for 
a 15 year period; it found the vaccine about 45% effective in preventing pneumonia and 75% 
effective in preventing invasive disease in general. (Musher & Rodriguez-Barradas, 2014)  
Pneumococcal polysaccharide vaccine can pose some difficulty since only about 80% of adults 
generate antibodies as a result of receiving it. Additionally, the antibody levels only remain 
significantly elevated for approximately five years.  While elevated it is estimated that protection 
is 70%. However,  those with chronic illnesses may have less protection. (Centers for Disease 
Control and Prevention, 2019)  Often patients feel it may be more effective and safer to get an 
illness naturally and avoid the unwanted side effects of exposure to chemicals in a vaccine and the 
injection experience itself.  However, exposing oneself to the Pneumococcus can be deadly.  
Pneumococcal pneumonia is the most common invasive infection due to developing an illness 
from Pneumococcus and if contracted in conjunction with influenza can yield a 20% death rate. 
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Post-mortem Pneumococcus was present in 27% of blood cultures from those flu victims. (Blasi, 
Mantero, PierAchille, & Tarsia, 2012) Additionally, overuse of antibiotics has led to the 
development of resistance and increased virulence. 
3.6 What are Barriers to Vaccination? 
Vaccine hesitancy is a well-known phenomenon and understanding the root causes 
continues to gather interest amongst people in the behavioral health, public health, and medical 
research communities. Attempting to better understand what behaviors govern individuals to 
choose to become vaccinated or allow their loved ones to be vaccinated has been studied 
extensively. Yet, limited research is available studying why adults in the United States particularly 
may refuse vaccinations generally speaking.  An abundance of research is available focusing on 
the measles vaccination in relationship to children. Influenza studies focus on special groups such 
as socioeconomically disadvantaged populations or a specific ethnicity. Gleaming information in 
an attempt to extrapolate some of the outcomes, it seems that misinformation and misinterpretation 
are huge factors that make individuals refuse a vaccine. Being able to understand what makes 
patients say no to something is imperative when attempting to affect vaccine hesitancy via a 
process improvement. 
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4.0 Literature Review 
Plenty of literature exists regarding childhood vaccination and addressing or affecting 
barriers to vaccination. Less has been written on adult barriers and programs to increase 
vaccination. The research does address several areas that go into the complexed decision patterns 
that help dictate whether individuals choose to receive a vaccine. An article by Albert Bach et al, 
“Addressing Common Barriers in adult immunizations: a review of interventions,” determined that 
when it comes to increasing vaccination rates in adults, reminder systems, access to vaccination, 
affordability of vaccine, and addressing social, ethnic, or culture differences in vaccination were 
areas that research has found relevant and thus research has focused on. Based on this literature 
review, it was generally determined that a multimodal approach is most likely to be effective; one 
that addresses not one single barrier but as many as possible, given resources. (Albert T. Bach, 
2019) Largely it has been determined that reminders via text messaging, phone calls, or cards 
significantly impact vaccination rates.  A review of randomized controlled trials in Medline from 
1966-1998 with updates from CINAHL and PubMed up through May 2007 by two independent 
reviewers looking at 47 studies involving reminder systems found that while there are varying 
rates of success, telephone reminders yielded the best results however were the most costly option. 
[adult pneumococcus, tetanus, and Hepatitis B (OR = 2.19, 95%CI = 1.21, 3.99), and adult 
influenza vaccinations (OR = 1.66, 95% CI = 1.31, 2.09).] (Jacobson Vann, 2005) 
Pharmacy based vaccination programs have also been shown to positively impact adult 
vaccination rates.  A study in human vaccines and immunotherapeutic cite that vaccination 
programs at pharmacies show an increased rate of influenza vaccination particularly among 
patients who may have previously missed their vaccine last year.  This study further breaks down 
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that both adults under 65 with a chronic condition and those older than 65 with or without chronic 
conditions show an increase in vaccination rates.  Many patients over 65 years of age experienced 
barriers due to Part D insurance coverage which may have influenced the overall vaccination rate 
in this subgroup. The under 65-year adult group with chronic illness like the elderly group is likely 
to seek vaccination per physician recommendation to reduce medical risks associated with 
comorbid illnesses at a higher rate than young healthy individuals.  The study population compared 
adults from Washington and Oregon states. Again, both states showed an increase in their 
vaccination rate based on the pharmacy intervention, but Washington state had a 4.7% higher rate 
of vaccination which suggests that pharmacy vaccination programs do have an overall impact but 
at varying rates depending on the region. (Burson, Buttenheim, Armstrong, & Feemster, 2016)  
Standing orders have also been studied in adult populations and found to be an effective way to 
help capture more eligible patients for vaccination in real time.  An article in the American Journal 
of Infection Control demonstrated a moderate increase in vaccination rates.   Measuring a baseline 
vaccination rate for 5 very different outpatient clinics and then measuring the change one year 
after implementing standing order protocols (SOPs) a 4-8% increase in rates was reported. These 
protocols help to alleviate the guess work at each patient encounter by standardizing the process 
and bypassing the need to obtain a physician order for each individual encounter.  Instead the order 
is inferred based on the patient medical history and guidelines set in place. The vaccines that were 
standardized were Tdap, influenza, pneumococcal, human papillomavirus, herpes zoster, and 
hepatitis B. (Tan, VanOss, Ofstead, & Wetzler, 2019)  
Studies have looked at what effect educating the physician has on adult vaccination 
practices by looking at an Internal medical residency.  A group of residents were trained versus a 
placebo group that did not receive additional education on immunizations.  This study found no 
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significant difference in the vaccination rates of their patients.  The study did find however that 
the resident physicians that did receive training felt more confident and more prepared to answer 
questions they received from patients. (Whitaker, et al., 2018) Educating patients too has varying 
effects due to the complex nature of the decision making process in an individual.   
While there are many approaches to increasing vaccination, a summation of multiple 
interventions has the multimodal effect suggested by Addressing Common Barriers in adult 
immunizations: a review of interventions. 
4.1 Project Participants 
4.1.1  AMGA 
The American Medical Group Association (AMGA) was founded in 1950 and is a non-
profit group that represents integrated health practices in the United States.  Its goal is to help to 
influence the delivery of,” patient-centered, high quality, value driven health care” (American 
Medical Group Association, 2020).   As a result of this mission, the Association spearheads several 
initiatives with the goal of providing high quality care and attempting to affect the health outcomes 
of a population rather than just an individual and moving the needle in a positive direction in 
healthcare.  Previous intervention programs that were developed under the AMGA emphasized 
blood pressure and diabetic care.  The AMGA does this by gathering medical groups large and 
small as participants to collaborate with each other to share tools, pitfalls and resources in order to 
aid groups in being successful in delivering care with value.  Although the AMGA sets goals for 
each project it strives to see any improvement that results in improved health outcomes, but 
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ultimately the AMGA ranks the groups and the top three groups present their data.  AMGA also 
joined forces with Optum analytics and Pfizer to help assist the medical groups. 
4.1.2  PMA 
PMA was established in 1993 and is the largest multi-specialty practice in the Western-
Pennsylvania.  It is located in the eastern suburbs of Pittsburgh, Pennsylvania. It currently is part 
of an integrated delivery system (Allegheny Health Network), a division of Highmark Health since 
2011.  It has approximately one hundred medical providers offering primary care for adults and 
children as well as several subspecialties including Cardiology, Allergy, Infectious Disease, 
Podiatry, Pulmonology, Endocrinology, Ophthalmology Radiology, Dermatology and General 
Surgery. A group that is quality driven, they obtained level three Patient Center Medical Home 
Recognition from the National Committee for Quality Assurance (NCQA). Premier reported 
377,000 patient occurrences in 2017 over 10 office locations (Colangelo, Crossey, Kahn, Kern, & 
Lyons, 2019). 
4.2 The Project Design 
In total, 39 medical groups comprised of various mixes of physicians, advanced care 
providers, nurses and practice managers across the country enrolled to participate. The initiative 
referenced in this paper was an adult vaccination program targeted at increasing vaccination rates 
in adults against Pneumococcus and Influenza.  Premier Medical Associates (PMA) participated 
in the Adult immunization Collaborative as one of the practices along with the author of this paper. 
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The author was involved through a preceptorship with Francis Colangelo, M.D., MS-HQS, the 
director of Quality at PMA, along with a group which included a nurse, another PMA physician, 
and an electronic health record technician.  Again, the goal of the collaborative was to increase the 
pneumococcal and influenza vaccination rate for adults in accordance to the AMGA collaborative 
guidelines. (Appendix A, B) The guidelines chosen by the AMGA were adapted from healthy 
people 2020. The guidelines specified that the project’s success be hinged upon three principles:  
education (provider and patient), targeted outreach, and implementation of standing orders.  A tool 
kit was provided to aid with formulating ideas for each category.  Additionally, the Center for 
Disease Control and Prevention’s (CDC) website was referenced for the current recommendations 
from the Advisory Committee for Immunization Practices (ACIP) for standard immunization 
guidelines. The Collaborative was one year long with a three-month post period to capture and 
report data. Three months prior to the onset of the AI Collaborative, a joint meeting amongst 
groups was held in Ohio where all the groups were educated on the incidence, prevalence, and 
morbidity associated with both Pneumococcus and Influenza. The groups were provided with 
helpful algorithms in order to clearly identify the target groups requiring vaccination.  Several 
additional webinars were given in January 2017 prior to the group’s launch.  The toolkit provided 
suggestions to help direct focus on changes that might have the greatest impact on program 
successes.  It also provided data mining support. The groups were to develop their own strategy to 
improve vaccination by implementing a plan from each of the categories: Provider Education, 
Patient Education, Information Technology, and Clinical Support. The categories were further 
subdivided into levels.  An intervention was required on each level that was offered. The categories 




1. Patients 65 years of age or older who received any pneumococcal vaccination with the 
healthy people 2020 goal 90% and collaborative goal 90% (measure1) 
 
2. Patients 65 years of age or older with both Pneumococcal polysaccharide vaccine (PPSV) 
and pneumococcal conjugate vaccine (PCV) with healthy people 2020 goal 90% and 
collaborative goal of 60%. (measure 1) 
 
3. Patients 19 to 64 years of age with immunocompromising chronic conditions (Appendix 
G immunocompromised conditions placing patients at High Risk), cerebrospinal fluid 
leaks or cochlear implants with healthy people 2020 goal 60% and collaborative goal 
(45%) (High Risk)(measure 2) 
 
4. Patients 19 to 64 years of age with decreased immune function (Appendix G 
immunocompromised conditions placing patients At-Risk](measure 2A- optional) 
 
5. Influenza vaccination with a collaborative with the Healthy people 2020 goal at 70% and 
the collaborative goat at 45%. (Table 2) (measure 3) 
 
Table 2 Collaborative Goals Compared to Healthy People 2020 Goals 
 
(Taken from Premier Medical Associates adult immunization (AI) Best Practice Learning Collaborative, 
Group 2: Case Study (2019) with permission) 
 
Although the Collaborative’s goals were extracted from the Healthy People 2020 goals, 
they were modified due to the short duration of the project. The goals were predetermined by the 
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collaborative organizers based on what degree of improvement that could realistically be 
accomplished in a year’s time. 
 
Provider Education 
Upon returning from the preparatory session, PMA held an All Provider meeting to educate 
the providers via a PowerPoint presentation which identified the populations to vaccinate with 
similar statistics about the illnesses as well as barriers to vaccination. This being a multispecialty 
group, it was emphasized that not just the primary care providers should attempt to engage a patient 
in regard to vaccination, but to offer it to them as it relates to the scope of their practice.  For 
example, an Allergist may encounter patients with asthma therefore offering vaccine for 
prevention of influenza is best practices guidelines and within scope of practice. Similarly, a 
Pulmonologist may see the need for prevention of both pneumococcus and influenza related 
illness. It was emphasized that universal vaccination for influenza is recommended by the ACIP.  
Additionally, PMA’s AI Collaborative group also informed the providers that there would be 
transparent reporting starting before the collaborative to prepare the providers and allow them time 
to develop a routine regarding their vaccination practices.   A monthly report of all providers in 
each department would be distributed and posted. Additionally, support would be offered for 
providers consistently unable to show results in alignment with their peers. 
Staff Education 
The guidelines for the AI Collaborative required a staff education piece, so in addition to 
the re-education piece provided to the providers, two other areas of education were the focus.  
Education was developed for the support staff of each of the offices.  The presentation was 
abbreviated from the larger one provided to the provider staff and the three physicians in PMA’s 
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collaborative rotated to each of the offices to give the education piece to each group during their 
staff meetings.  This was thought to be a big component of the program since the support staff’s 
attitudes toward vaccination even if unspoken would have a large impact on how the vaccine would 
be received by the patients they were caring for.  In order to tailor the presentation to the staff, a 
survey was developed on survey monkey and sent to staff to gather questions, myths and concerns 
regarding vaccinations. (Appendix C) The questions that were similar in content were grouped 
together and most were incorporated during the educational PowerPoint presentation.  Any 
additional questions were addressed during the post discussion. The staff was then given short 
phrases or talking points to use when patients asked them questions regarding the vaccine efficacy 
or safety.  They were also encouraged to refer the patient to have further discussion with their 
provider. The desired approach was to have the patient receive a unified and consistent message 
regarding vaccination. The patient care workflow was redesigned to open the conversation 
regarding the vaccines needed at the beginning of the visit along with giving the information sheets 
that were discussed in the patient education section. (Appendix D,E) It was also an opportunity for 
the support staff to streamline the vaccination process if the patient was interested in vaccination 
so that it could occur even before meeting with the provider and therefore more of the visit could 
be used to address other medical concerns. 
Patient Education 
It was expected that three levels of patient education be provided.  First, an adult 
immunization fact sheet was created as tear-off (Appendix D, E) to be offered for patients in the 
office while they were waiting for their appointments. This sheet was prepared in alignment with 
the information given the staff to add to congruency of the message.  The information on the fact 
sheet was created in conjunction with information given from the toolkit and from the CDC 
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websites. Next a message regarding pneumococcal morbidity and the possible need for a vaccine 
was added to the patient portal for relevant age groups. (Appendix F) The message was viewed if 
the patient logged onto their healthcare portal for any reason.  It encouraged the reader to call their 
primary care provider’s office to see if they are protected. The final education piece involved 
implementing a rolling message on the phone lines to share times and locations for obtaining the 
influenza vaccination.  The tear-offs and the electronic message provided reference details and 
visual reinforcement regarding the needed vaccination. 
Information Technology 
To meet the requirements for information technology at all levels, standardization of 
documentation in the electronic medical record and tracking of the patient’s immunization status 
via an electronic dashboard were two workflow protocols that were in place and had been routinely 
used in the past. As a result of using them to capture a patient’s immunization status in real-time 
and then immediately encourage vaccination while in the office, this portion of the program was 
effortless. Providers and their clinical support teams were reminded to check the electronic dash 
boards in the electronic health record to see if the patient needed either vaccine when preparing 
for the patients encounter for the following day.  This method is equivalent to what is considered 
point of care alerts or electronic reminders. The dashboard also served to generate the monthly 
transparency reports that were discussed above. Additionally, the power of electronic medical 
records was utilized to obtain registries of patients that were deficient in both pneumococcal and 
influenza vaccines.  The support staff then called these patients and attempted to schedule them 
for a visit to obtain their needed vaccine. Optum analytics also provided several automated call 
sessions via an artificial intelligence phone tool called Expectation Management and Medical 
Information (EMMI) at various times of day in order to attempt to reach a larger range of patients.  
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Clinical Support 
The goal for clinical support was to ultimately help to intertwine the loose ends that 
regularly occur in patient care and to help to make each patient interaction a successful opportunity 
to get the patient vaccinated. To do this, it required keeping the staff healthy by administering flu 
vaccine to them and thereby creating a layer of protection for the patients they would encounter as 
well; some of which had weakened immunity. Intensive discussions surrounding mandating 
vaccine for staff occurred but ultimately an incremental approach was felt to be warranted given 
the instability of the staff volume.    Next, care coordinators would call eligible patients or talk to 
patients who called in for other matters and offer to assist them in scheduling for vaccination. 
Standing orders overlapped with staff education. It was instituted so that after the staff had been 
thoroughly educated to address vaccine questions, they could proceed with vaccination without 
waiting for a doctor’s order.  The final piece for the clinical support staff was to seize the 
opportunity to vaccinate patients while in the office regardless of the reason for their visit which 
often wasn’t related to vaccination.  There were additional opportunities for patients to get a flu 
vaccine with flu clinics done at multiple Premier sites with a variety of extended hours for 
convenience.  The flu and pneumococcal vaccine were offered to all patients being discharged 
from the hospital.  When appropriate, that updated immunization status was coordinated with 
skilled nursing facilities caring for those patients. The criterion also had a compensation 
component.  This was not a main focus of the collaboration for PMA yet still an important one.  
Affordability of vaccines is a serious concern for patients and recouping the cost of administering 
the services is imperative in keeping a business operational.  These aspects were handled by the 
revenue cycle team based on ICD-10 codes that the electronic health record team selected with 
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guidance from the toolkit. There was no interaction with the author and the revenue cycle team, 
and this was not a focus of this paper. 
Results 
The results show that Premier exceeded all goals set by the AMGA for measures 1, 2 and 
3. (Tables 3-6) Optional measure 2a. had no set goal but was reported as a useful measure that an 
organization could use to follow the at-risk population of patients that they care for. Prior to the 
official start of the measuring period Premier had met the target goals in both measure 1 and 
measure 3, during the collaborative the vaccine rates continued to increase with no plateau.  These 
results were later shared with collogues that also participated in the collaborative in an effort to 
learn for successes as well as pitfalls experienced with the common goal of improving patient 
outcomes.  Organizations participating varied in size from similar sized medical practices to larger 
institutions.  Although the groups must remain anonymous, Premier showed the largest 





















Table 5 Measure 2A Results - Pneumococcal (Any) Immunization for Adults Ages 19-64 with At-risk Conditions 
 
 





During the study, the robotic call tool better known as EMMI contacted 5707 patients in 
total who were deemed eligible to receive vaccination based on the information harvested from 
the Allscripts electronic health records. (Table 7) 
Table 7 EMMI Phone Results 
  
(Taken from Premier Medical Associates adult immunization (AI) Best Practice Learning Collaborative, Group 2: 
Case Study (2019) with permission) 
 
The robocall message was personalized with the patient’s provider information and 
successfully contacted two thousand six hundred and seventy-six patients (46%) resulting in nine 
hundred and thirty-five patients (34%) receiving vaccination for one or more of the vaccines for 
which they were eligible. The system offered an option of conveniently speaking directly to a staff 
member during normal hours to schedule or alternatively calling for an appointment later. The 
latter option was offered solely afterhours. At the conclusion of the study, the results were 






Table 8 Final Premier Results Compared to Collaborative Goals 
(Taken from Premier Medical Associates Adult Immunization (AI) Best Practice Learning Collaborative, Group 2: 
Case Study (2019) with permission 
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5.0 Discussion 
It is safe to say that Premier’s efforts to implement changes through the education of 
physicians, support staff and patients were successful.  Looking at the project as a whole, 
transparency was a large contributor to its success. Based on a prior Human papilloma virus (HPV) 
improvement initiatives done by Premier it was noted anecdotally that posting each provider’s 
results seemed to drive the efforts such that the top providers tried to stay of top and the lower 
providers brought up their results by the next reporting period.  This is also seen annually with 
influenza vaccination.  Collectively, each person’s efforts of trying not to appear to have the 
weakest performance moves the group as a whole towards its efforts. 
Telling the physician that their metrics would be followed and shared with their colleagues 
made a huge impact on their behavior.  It is a phenomenon that Premier witnessed during other 
improvement projects that they participated in.  It appears that most physicians prefer not to be at 
the lower end of performance outcomes and feel ashamed in a way when they are not at the top.  
While this is not the sole reason for their performance, it is certainly a contributing factor. Other 
elements that lead to such positive outcomes were educating the staff to display a message that 
was harmonious in its delivery by everyone interacting with the patient. By no means does that 
imply that all skepticism that the patient had was dissolved, but it seems to resonate with some 
patients and made them reconsider vaccination if there was any room to budge them. Affecting 
this skepticism is a much harder task when it comes to a vaccine such as influenza.  While 
acceptance for the Pneumococcal vaccine uptake fell higher, influenza vaccine continues to seem 
stigmatized.  The concerns that it may cause illness or debility plagues it along with its need for 
recurring revaccination. So many people have a level of discomfort with this vaccination and the 
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ability to counteract doubt with fact and a repetitious message must remain the goal.  Meeting the 
staff where they were by specifically addressing the questions they had and giving them responses 
to use when they encountered patients with similar feelings was crucial.  EMMI was a tremendous 
addition to the outreach part of this project.  Robocalling can reach a far greater number of patients 
in a shorter amount of time as compared to manually calling. It provided the game changing ability 
to call multiple times even during off hours.  The personalization of the messages gave a feel that 
each patient was receiving a message directly from his/her provider. Even though people often 
don’t prefer automation to a personal touch EMMI did get engagement in a large number of eligible 
participants and it clearly impacted the outcomes.  The use of EMMI freed our support staff to call 
those who were eligible to receive vaccine but did not engage with EMMI.  EMMI made this 
subset of patients a more manageable number.  It was decided on certain time blocks for EMMI to 
begin calling.   Selection of certain times generated a selection bias and perhaps impacted the 
number of responses since selecting particular periods may eliminate those who may not routinely 
be home to accept a call during that period.  There is no way to completely fix this barrier but call 
times were staggered in an effort to reach some patients during the day and in the evening. Not 
every practice group involved in the AI chose to utilize EMMI.  The case study was performed by 
various sizes and types of practices and there were vast differences in the vaccination rates.  Result 
variability was multifactorial but since each group choose what plans they were planning to 
implement from each category it is difficult to speak on exactly why one group had a certain 
outcome over another one. The results of each group were not able to be shared nor is it really 
relevant to Premier’s outcomes since each group worked individually.  The salient point is that 
while Premier’s population health successes were significant, they are not generalizable.  It was 
not easy to separate out what degree of impact was made by each change: education, SOP’s, 
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messaging and reminders.  Doing all of them simultaneously had an additive effect.  While all 
other groups experienced some improvement in their adult immunization rates, other factors such 
as patient demographics and regional related differences may have affected outcomes. Moreover, 
the goal would be to use the information learned from this collaborative and its generalities to 
effect change by instituting reminders, education, SOP’s, and transparency.  Fortunately, Premier’s 
experience in collaboratives along with a certain work culture helps them to continue to do well in 
theses collaboratives thus helping them to deliver a higher quality of care at a lowest cost.   
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6.0 Limitations 
When looking at areas that presented a heavy lift for the programming team, it can 
definitely be said that the leanness of the group presented a problem.  The group was comprised 
of the Quality Director, a quality clinician, two physician team members, and an information 
technologist. Other teams had a greater number of participants and therefore they could distribute 
various tasks amongst a wider array of people and additionally had more people to help brainstorm 
ideas to meet goals.  Thankfully most of the team had been involved in population health initiatives 
before. As a result, they knew how to streamline different aspects of the project and had knowledge 
regarding what types of tasks didn’t seem to work for Premier in the past given the patients 
population-provider mix.   
While robocalls helped to reach a large number of people in a short time, the times chosen 
to send the calls presented a selection bias. There were times that the calls went out and some 
people may not have been home to answer.  An attempt to rotate times was done but could not 
guarantee that everyone eligible would be contacted. Furthermore, there are individuals who hang 
up on computerized calls which hinders their engagement with the phone service. As reported 
earlier, limited manpower prohibits a staff person from calling a large number of people and the 
number of staff available on any given day for vaccination, calls, or any other related duties can 
vary from day to day. 
It is probable that more patients were vaccinated than were captured, but we were unable 
to know to what magnitude because if they were vaccinated at a local pharmacy, the pharmacy 
does not automatically share that information with the patient’s provider.  There is a large number 
of pharmacies in the area depending on insurance practices so trying to obtain that information 
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would be best done through a policy change mandating that information be shared instead of the 
current protocol of relying solely on the patient who may have the best intentions to give this 
information to the provider.  Another care gap that was exposed is the lack of bidirectional 
reporting between Premier’s electronic record with other medical services as well as the absence 
to a statewide immunization registry with bidirectional reporting.  Without bidirectional 
communication between electronic health systems, a patient can receive a vaccination at a retail 
store, pharmacy, or at urgent care, but the recipient does not have that information automatically 
transmitted to the patient’s primary care provider.  Automatic transmission helps to keep records 
up to date to prevent a vaccine from being administered in duplicate. Such software is under 
development for different medical record systems to have the ability to be able to share data in 
real-time.  The statewide registry can act as a database to store patient immunization records and 
to make them accessible for any provider or the patient themselves.  Pennsylvania does have a 
registry, but unfortunately it is only collecting data at the time of this project. Its collections are 
not bidirectionally shared. 
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7.0 Conclusion/Recommendations 
Every participant group in the AI collaborative noted improvements on some level.  Our 
results exceeded the collaborative goals.  This can be contributed to the multimodal approach 
allowing each change to contribute to yielding some level of improvement. While it is unclear to 
what degree each change contributed, it is probable that each change had some effect. Not every 
intervention started simultaneously, yet we were able to see improvements throughout our monthly 
monitoring. Reminder phone calls have been scientifically shown to increase vaccine rates. Our 
robocall engaged 40-70% of each group with 19-40% of the groups being vaccinated as a result.  
Other reminders were also done manually from nurses who reviewed lists of patients who may be 
eligible for vaccine but hadn’t had some contact with the medical office or responded to outreach. 
The staff calls were more personal but are more expensive and labor intensive.  The SOP’s helped 
to make it easier for those patients coming in to receive vaccination without waiting to see the 
doctor.  Additionally, if patients were in the office for other reasons, they could conveniently be 
vaccinated it desired. Flu clinics eliminated the need for an appointment. All of these changes 
removed barriers to vaccination.  It is difficult to translate what educating the providers and staff 
did for the overall immunization rates. Making the staff comfortable to be able to engage the 
patient on a topic that may bring some resistance is difficult, but it at least starts the conversation 
and dispels myths. 
Based on this process improvement, it is recommended to continue a reminder system that 
can call a large number of eligible patients for vaccination based on information harvested from 
the electronic health record. It is important to maintain the staff education in an annual training 
and for new hires and to help keep their educational message current. Standard order protocols 
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help streamline the interoffice process and should continue. Transparent reporting amongst 
physician has remained successful, is easy to maintain, and should continue. It helps to keep an 
expectation present. Lastly, it would be very advantageous to work on a system to automate 
pharmacy vaccination information or at the very least have a pharmacy employee have a 
responsibility to send this information to the patient’s healthcare team. This project serves to 
demonstrate some interventions that improved vaccination outcomes. While there were many other 
things that could have been done to increase the vaccination rates, general education of all that are 
involved, outreach to help the patient engage and understand the vaccine’s importance, and 






































Appendix C Survey Monkey Flu Vaccine  
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Appendix D Patient Education - Pneumococcal Disease 
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Appendix E  Patient Education - Influenza 
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Appendix F Electronic Portal Statements 
Portal Statement for Pneumococcus 
Pneumococcal disease comes from bacteria called Pneumococcus.  It is a big 
cause of pneumonia, blood infections and meningitis.  These infections are more 
likely as you age.  Your risk for these illnesses also increases if you have heart 
disease, diabetes or lung disease.  There’s good news; you can be vaccinated to 
be protected against this very serious and potentially life-threatening illness.  
Please call us to make an appointment for the vaccine.   You may know of a loved 
one that may need this protection. Please share this information with them. If you 
have already received this vaccine somewhere else, then contact us to update 
your records.  Be well! 
 
 
Portal Statement for Influenza 
Influenza is a highly contagious respiratory illness. It can cause mild to severe 
illness that can lead to hospitalization or death. Those with chronic medical 
condition such as diabetes, asthma, heart disease or pregnancy may have serious 
illness if they contract the flu.  The best way to prevent this is by getting a flu 
shot.  The CDC recommends this vaccine for 6 months and older yearly to reduce 
your chances of getting sick. It’s important to vaccinate yourself if you have close 
contact with loved ones that may have a weakening immune system or unable to 
get a vaccine for themselves. Please call us to make an appointment for the 
vaccine.  If you have received this vaccine somewhere else, then contact us to 
update your records.  Be well! 
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Appendix G High Risk/At Conditions for Pneumococcal Illness 
High Risk Conditions for Pneumococcal Vaccination 
 
• Sickle Cell disease/other hemoglobinopathy 
• Congenital or acquired asplenia 
• Congenital or acquired immunodeficiency 
• HIV infection 
• Chronic renal failure 
• Nephrotic syndrome 
• Leukemia 
• Lymphoma 
• Hodgkin’s disease 
• Generalized Malignancy 
• Iatrogenic immunosuppression 
• Solid organ transplant 
• Multiple myeloma 
 
At-Risk Conditions for Pneumococcal Vaccination  
 
• Chronic heart disease 
• Chronic lung disease 
• Diabetes mellitus 
• Alcoholism 
• Chronic liver disease, cirrhosis 




ACIP: Advisory Committee on Immunization Practices  
AI Collaborative: AMGA’s Adult Immunization Best Practices Collaborative 
AMGA: American Medical Group Associations 
APP: Advanced practice provider 
CDC: Centers for Disease Control and Prevention  
EHR: Electronic health record 
FLU: influenza 
HP2020: Healthy People 2020 
PCV: Pneumococcal conjugate vaccine 
PMA: Premier Medical Associates 
PPSV: Pneumococcal polysaccharide vaccine  




Albert T. Bach, A. Y. (2019). Addressing common barriers in adult immunizations: a review of 
interventions, Expert Review of Vaccines. Expert Review of Vaccines, 1167-1185. 
American Medical Group Association. (2020, January 13). AMGA. Retrieved from amga.org: 
https://www.amga.org 
Blasi, F., Mantero, M., PierAchille, S., & Tarsia, P. (2012). Understanding the burden of 
pneumococcal disease in adults. Clinical Microbiology and Infection, 7-14. 
Burson, R. C., Buttenheim, A. M., Armstrong, A., & Feemster, K. A. (2016). Community 
pharmacies as sites of adult vaccination: A systematic review. Human vaccines & 
immunotherapeutics, 3146-3159. 
Center's for Disease Control and Prevention. (2013, February). Understanding how Vaccines 
Work. Retrieved from cdc.gov: https://www.cdc.gov/vaccines/hcp/patient-
ed/conversations/downloads/vacsafe-understand-bw-office.pdf 
Centers for Disease Control and Prevention. (2019, September). National Center for Health 
Statistics. Retrieved from cdc.gov: https://www.cdc.gov/nchs/fastats/immunize.htm 
Center's for Disease Control and Prevention. (2019, October). Pneumococcal Disease. Retrieved 
from cdc.gov: https://www.cdc.gov/pneumococcal/drug-resistance.html#trends  
Center's for Disease Control and Prevention. (2019, September). Recommended adult 
Immunization Schedule for ages 19 years or older, United States, 2019. Retrieved from 
cdc.gov: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-shell.html#note-pneumo 
Centers for Disease Control and Prevention. (2019, Auguest). Vaccination Coverage Among 
Adult in the United States, National Interview Survey,2016. Retrieved from cdc.gov: 
https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-
resources/NHIS-2016.html  
Centers for Disease Control and Prevention. (2019, November 12). Vaccines and Preventable 
Disease. Retrieved from cdc.gov: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-
vaccine.html 
Centers for Disease Control and Prevention. (n.d.). Influenza (Flu) For Clinicians: Vaccine 
Safety. Retrieved from CDC.gov: 
https://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm 
 48 
Colangelo, F., Crossey, R., Kahn, N., Kern, H., & Lyons, T. D. (2019). Adult Immunization (AI) 
Best Practices Learining Collaborative, Group 2: Case Study. Pittsburgh: AMGA 
Foundation. 
Fisher, M. P., Gurfinkel, D., & Szilagyl, A. (2019). Supporting and sustaining centralizee 
reminder/recall for imminizations: Qualitative insights from stakeholders. Vaccine, 264-
410. 
Gomez Lorenzo, M. M., & Fenton, M. J. (2013). Immunobiology of Influenza Vaccines. Chest, 
502-510. 
Influenza. (2019 October). Retrieved from cdc.gov: 
https://www.cdc.gov/flu/about/burden/index.html 
Jacobson Vann, J. C. (2005). Patient reminder and recall systems to improve immunization rates 
. Patient reminder and patient recall systems to improve immunization rates. The 
Cochrane database of systematic reviews, CD003941. 
doi:10.1002/14651858.CD003941.pub2. 
Kelso, J. M. (2018). Administrating influenza vaccine to egg-allergic persons. Expert Review of 
Vaccines, 1049-1057. 
Matanock A, L. G. (2019). Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent 
Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated 
Recommendations of the Advisory Committee on Immunization Practices. . MMWR 
Morbitiy and Mortality Weekly Report, 1069-1075. 
Merch Manual Professional Version. (2019, October). Influenza. Retrieved from 
merchmanuals.com: https://www.merckmanuals.com/professional/infectious-
diseases/respiratory-viruses/influenza 
Merck Manual. (2019, June). Merck Manual Professional version Pneumococcal Infections. 
Retrieved from marckmanual.com: 
https://www.merckmanuals.com/professional/infectious-diseases/gram-positive-
cocci/pneumococcal-infections#v1005121 
Musher, D., & Rodriguez-Barradas, M. (2014). The CAPITA study of protein-conjugate 
pneumococcal vaccine and its implications for use in adults in developed countries. 
Human Vaccines and Immunotherapeutics, 1331-1333. 
Puturi, W., Muscatello, D. J., Stockwell, M. S., & Newall, A. (2018). economic burden of 
seasonal influenza in the United States. Vaccine, 3960-3966. 
Rappuoli, R., Pizza, M., & DeGregorio, E. (2014). Vaccines, new opportunities for a new 
society. Proceedings of the National Academiy of Sciences of the United States of 
America, 12288-12293. 
 49 
Rappuoli, R., Pizza, M., Del Giudice, G., & De Gregorio, E. (2014). Vaccine, new opportunities 
for a new society. Proceeding of the National Academy of Sciences of the United States of 
America, 12288-12293. 
Riedel, S. (2005, January). Edward Jenner and the history of smallpox and vaccination. 
Proceedings ( Baylor University Medical Center), pp. 21-25. 
Rondy, M., El Omeiri, N., Thompson, M., Leveque, A., Moren, A., & Sullivan, S. (2017). 
Effectiveness of influenza vaccines in preventing severe influenza illness among adults: 
A systematic review and meta-analysis of test-negative design case- control studies. 
Journal of Infecton, 381-394. 
Shen, A. K., Warnock, R., Selna, W., Chu, S., & Kelman, J. A. (2019). Patient characteristics of 
Medicare beneficiaries who report not getting influenze and pneumococcal vaccination 
2001-2013. Human Vaccines and Immunotherapeutics, 1-7. 
Tan, L. J., VanOss, R., Ofstead, C. L., & Wetzler, H. P. (2019). Maximizing the impact of, and 
sustaining standing orders protocols for adult immunization in outpaient clinics. 
American Journal of Infection Control. 
Wehbi, N. K., Wani, R. J., & Kleoser, D. G. (2019). Impact of implementing a technology 
platform in community pharmacies to increase adult immunization rates. Vaccine, 56-60. 
Whitaker, J. A., Poland, C. M., Beckman, T. J., Bundrick, J. B., Chaudhry, R., Grill, D. E., . . . 
Huber, J. M. (2018). Immunization education for internal medicine residents: A cluste- 
randomized controlled trial. Vaccine, 1823-1829. 
 
 
 
 
 
